Poppies & pills in the Golden Triangle: The resilience of the Asian drugs market and the failure of prohibitionist policies

Publications

Poppies & pills in the Golden Triangle: The resilience of the Asian drugs market and the failure of prohibitionist policies

17 November 2026

In the past decade, illegal drug markets in Southeast Asia and around the world have continued to expand and diversify, with key shifts in production, distribution and policy patterns. Synthetic drug production and consumption – particularly amphetamine-type stimulants – have both risen sharply. Opiates remain popular in some Southeast Asian countries, serving as a psychoactive substance, a traditional medicine and a source of income for impoverished rural communities. Meanwhile, Thailand became the first country in Southeast Asia to develop legal and decriminalized cannabis and kratom markets, radically departing from the zero-tolerance approach that still dominates the region.

The Covid-19 pandemic and various global developments – from growing geopolitical instability and rising socioeconomic inequality to the worsening climate crisis – have undoubtedly impacted drug markets as well. However, illegal drug markets remain highly adaptive, continuing to expand in size and diversity despite ongoing enforcement efforts worldwide, including in Southeast Asia. As such, drug market dynamics are inseparable from policy patterns. Market forces and policy responses continually shape one another, together affecting people and communities.

As documented in the TNI reports “Withdrawal Symptoms” (2009) and “Bouncing Back” (2014), prohibition-based policies have failed to address structural inequalities; this report examines how these dynamics have since evolved. Building on earlier publications, this report documents changes in drug markets in Southeast Asia and the wider region and analyses how they interact with social, economic, and political dynamics. Whilst it is crucial to document and respond to the harms associated with drug markets, one must also recognise people and communities who depend on these markets for survival, especially where legal and viable livelihoods are lacking. Having said that, this report deliberately refrains from problematising and pathologising language, aiming instead for a realistic description and analysis of drug markets and their consequences, especially regarding the welfare and well-being of local communities affected by them. In this regard, indicators such as health, welfare, and human rights are put at the forefront and given primacy over quantitative indicators such as drug and precursor seizures.

When analysing drug markets in Southeast Asia, it is also essential to be critical of prevailing – and in some cases increasingly harsh and unjust – policies and their impact on communities. These policies concern not only drugs, but also land, gender, labour, and other interconnected issues. This is why this report focuses on the experiences and voices of communities, highlighting intersectional factors that increase vulnerability while concentrating power and wealth among a few.

Research for this report began shortly prior to the Covid-19 pandemic but was delayed by the global health crisis and, in Myanmar, the military coup of 2021. While these events slowed down data collection, the pause also allowed for deeper reflection and engagement with communities on their effects. Researchers conducted dozens of interviews and field observations between 2019 and 2024, creating a richer body of evidence over time.

This report takes a qualitative approach, prioritising lived experiences over statistics such as prevalence or seizure volumes. It draws on interviews and analyses gathered by trusted partners and organisations in Myanmar, Northeast India, China, Thailand, Bangladesh, and to a lesser extent Indonesia and Vietnam. These contributions highlight the diversity and complexity of communities involved in or affected by drug markets, particularly those ignored in mainstream narratives.

This report does not offer absolute truths but rather seeks to contribute to ongoing debates on drug policy and social justice in Southeast Asia and the surrounding region. It does not claim a monopoly on expertise but aims to raise critical questions about whose interests current policies serve and at what cost. In addition to insights into drug market dynamics, the report puts forward proposals for policy and data collection that place social justice at their core. These include frameworks to support community well-being, reduce harm and uphold human rights – while acknowledging the structural barriers to turning such principles into reality.

The data gathered for this report confirm a clear trend: drug use prevalence in Southeast Asia is rising, as it is elsewhere in the world, despite massive enforcement spending and Covid-19 restrictions. While drug use has become more accepted in certain age groups and professions, people who use drugs still face stigma and criminalisation. There is an increasing diversification of drugs on the market, and social, economic and cultural circumstances are determining the drugs of choice. At the same time with the rising drug use prevalence in Southeast Asia more and more people are incarcerated, especially the number of female prisoners has been rising steadily over the past 5 years. According to the UNODC 2025 World Drug Report, “the criminalization of drug use and resulting incarceration of people who use drugs or have drug use disorders have high costs, both direct and indirect, for individuals, their families and the community.”

It is a positive development that Thailand has reviewed its drug legislation and decriminalised cannabis and kratom, despite regularly returning risks of re-criminalisation with each change in government. The decriminalisation is viewed critically by some ASEAN member states, while Malaysia has shown interest in following Thailand’s path. Meanwhile, knowledge of harm reduction as a self-help strategy is increasing, and conscious self-regulation of use is gaining ground.